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Cerebral Small Vessel Disease and Association With
Higher Incidence of Depressive Symptoms in a General
Elderly Population: The AGES-Reykjavik Study
Thomas T. van Sloten, M.D., Sigurdur Sigurdsson, M.Sc., Mark A. van Buchem, M.D., Ph.D., Caroline L. Phillips, M.S.,
Palmi V. Jonsson, M.D., Jie Ding, Ph.D., Miranda T. Schram, Ph.D., Tamara B. Harris, M.D., M.S.,
Vilmundur Gudnason, M.D., Ph.D., Lenore J. Launer, Ph.D.
Objective: The vascular depression hypothesis postulates
that cerebral small vessel disease (CSVD) leads to depressive
symptoms by disruption of brain structures involved inmood
regulation. However, longitudinal data on the association
between CSVD and depressive symptoms are scarce. The
authors investigated the association between CSVD and in-
cident depressive symptoms.
Method: Longitudinal data were taken from the Age, Gene/
Environment Susceptibility-Reykjavik Study of 1,949 partic-
ipants free of dementia and without baseline depressive
symptoms (mean age: 74.6 years [SD=4.6]; women, 56.6%).
MRImarkers of CSVD, detected at baseline (2002–2006) and
follow-up (2007–2011), includedwhitematterhyperintensity
volume, subcortical infarcts, cerebral microbleeds, Virchow-
Robin spaces, and total brain parenchyma volume. Incident
depressive symptoms were defined by a score$6 on the 15-
itemGeriatric Depression Scale and/or use of antidepressant
medication.
Results: Depressive symptoms occurred in 10.1% of the par-
ticipants. The association for a greater onset of depressive
symptoms was significant for participants with 1 standard de-
viation increase in white matter hyperintensity volume over
time, new subcortical infarcts, new Virchow-Robin spaces, 1
standard deviation lower total brain volume at baseline, and 1
standarddeviationdecreasedtotalbrainvolumeover time,after
adjustments for cognitive function and sociodemographic and
cardiovascular factors. Results were qualitatively similar when
change in the Geriatric Depression Scale score over time was
used as the outcome instead of incident depressive symptoms.
Conclusions:MostmarkersofprogressionofCSVDover time
and some markers of baseline CSVD are associated with
concurrently developing new depressive symptoms. These
findings support the vascular depression hypothesis.
Am J Psychiatry 2015; 172:570–578; doi: 10.1176/appi.ajp.2014.
14050578
Depressive symptoms are often present in older individuals
(1–4) and are associated with an increase in morbidity and
risk for mortality (5, 6). The pathobiology of late-life de-
pressive symptoms is incompletely understood, but it has
been suggested that cerebral small vessel disease (CSVD) is
involved (7, 8).Thevasculardepressionhypothesispostulates
that CSVD leads to depressive symptoms by disruption of
deep and frontal brain structures or their connecting path-
ways involved in mood regulation (7, 8).
However, longitudinal data (9–17) on the association be-
tween CSVD and depressive symptoms are limited, and
findings are mixed. Two previous studies (12, 13) found an
association between markers of CSVD and incident de-
pressive symptoms. Additionally, three studies (9, 15, 16)
showed an association with increased severity or recurrence
of depressive symptoms at follow-up but not with incident
depressive symptoms, whereas two other studies (11, 17) did
not find any association with depressive symptoms. These
mixed findingsmay be a result of study differences in sample
size, follow-up duration, and the method of depression as-
sessment (clinical interview [12–15] versus questionnaire
[9–11, 16, 17]), as well as evaluation of different symptom
clusters and differences in the source of populations in-
vestigated (selected [9, 10, 12, 17] versus community-based
samples [11, 13–16]). Furthermore, some studies didnot adjust
the results for potential important confounders, such as
cognitive function (11, 13, 14, 17) and cardiovascular factors
(12, 15, 17).
In viewof the above issues, we investigated, in a largewell-
characterized cohort, the prospective association between, on
the one hand, markers of CSVD (white matter hyperintensity
volume, subcortical infarcts, cerebral microbleeds, Virchow-
Robin spaces, and lower total brain parenchyma volume) and,
on the other, incident depressive symptoms. We additionally
investigated whether any such association was stronger for
CSVD in brain regions involved in mood regulation (deep
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For the present study, we used longitudinal data from the Age,
Gene/Environment Susceptibility (AGES)-Reykjavik Study.
TheAGES-Reykjavik Study is a population-based cohort study
originating from the Reykjavik Study, as described in detail
elsewhere (18). Briefly, from 2002 to 2006, a total of 5,764
surviving participants from the Reykjavik Study were exam-
ined. From2007 to 2011, therewas a follow-up examination of
all surviving participants who agreed to participate (N=3,316).
Reasons for not attending the follow-up examination included
death (N=1,039), refusal (N=1,198), and lost to follow-up (could
not be contacted by any means; N=211). The AGES-Reykjavik
Study was approved by the National Bioethics Committee in
Iceland (approval number, VSN-00–063) and by the National
Institute on Aging Intramural Institutional Review Board.
After complete description of the study was provided, written
informed consent was obtained.
Depressive Symptoms
Depressive symptoms were assessed in all participants with
the 15-itemGeriatric Depression Scale (score range: 0–15) (19,
20). Incident depressive symptoms were defined as a pre-
definedGeriatric Depression Scale cut-off score$6 (19, 20) at
follow-up and/or new use of antidepressant medication (tri-
cyclics, selective serotonin reuptake inhibitors [SSRIs], other
nontricyclics, and monoamine oxidase inhibitors) assessed
frommedicationbottles brought to theclinic. Individualswere
excluded from the present analysis if they had depressive
symptoms at baseline (score$6 and/or use of antidepressant
medication at baseline).
Brain MRI Measures
Image acquisition.All eligible participantswere scannedwith
high-resolution brain MRI acquired on a study-dedicated
1.5-T system (Signa Twinspeed, General Electric Medical
Systems,Fairfield,Conn.).Thesameimagingprotocolwasused
in the 2002–2006 and 2007–2011 examinations, as described
elsewhere (21, 22), and included the following sequences:
three-dimensionalT1-weightedspoiled-gradient recalledecho,
proton density/T2-weighted fast spin-echo, fluid-attenuated
inversion recovery, and T2*-weighted gradient-echo type echo
planar.All imageswereacquired togive fullbraincoveragewith
slices angled parallel to the anterior commissure-posterior
commissure line in order to yield reproducible image views
in the oblique-axial plane.
Image analysis. Several markers of CSVD were evaluated.
White matter hyperintensity volume and total brain paren-
chyma volume (an indicator of cerebral atrophy) were com-
putedautomaticallywithapreviouslydescribedimageanalysis
pipeline (23) and were expressed as the percentage of total
intracranial volume. Lower total brain parenchyma volume
was considered to be a marker of CSVD, since CSVD leads to
generalized loss of brain parenchyma through, among other
processes,microinfarcts (24) and lossofwhitematter integrity
(25). Subcortical infarcts were evaluated as previously de-
scribed (21) and defined as brain parenchyma defects not
extending into the cortex, with a minimum diameter of 4 mm
and a signal intensity equal to CSF on all pulse sequences
(T2-weighted, proton density-weighted, and fluid-attenuated
inversion recovery), and surrounded by an area of high-signal
intensity on fluid-attenuated inversion recovery images. Pa-
renchymal defects in the subcortical area with evidence of
hemosiderin on the T2*-weighted gradient-echo type echo
planar scan were labeled as resorbed hematomas and were
excluded from the definition of subcortical infarcts. Virchow-
Robin spaceswere evaluated separately and defined as defects
in the subcortical area without a rim or area of high-signal
intensity on fluid-attenuated inversion recovery and without
evidence of hemosiderin on the T2*-weighted gradient-echo
type echo planar scan. Presence of Virchow-Robin spaceswas
considered to be a marker of CSVD, since they are associated
with endothelial dysfunction, which may play a role in the
pathogenesis of CSVD (26). Cerebral microbleeds were de-
fined as focal areas of signal voidwithin the brain parenchyma
visible on T2*-weighted gradient-echo type echo planar scans
and were identified as previously described (22).
Potential Confounding Variables
As described elsewhere (18), dementia case-finding was con-
ducted at baseline and at follow-up according to a three-step
procedure. Diagnosis of dementia (all subtypes) was made
according to DSM-IV criteria by a panel that included a geri-
atrician, a neurologist, a neuropsychologist, and a neuroradi-
ologist.Thefollowingvariableswereassessedbyquestionnaire:
education (categorized as primary, secondary, and college/
university education), smoking history (ever versus never),
alcohol intake (high [.median] versus low [,median] con-
sumers; median for women and men, 3.2 g per week and 8.0 g
per week, respectively), and anxiety symptoms (presence
versus absence). Presence of anxiety symptomswas defined by
a positive response to any of the following questions: “In the
pastmonth, have you felt anxious or frightened?”; “Were there
times lately that youfelt anxious?”; “Arethere special situations
thatmakeyouanxious?”; and “Haveyoueverhadattacksof fear
or panic?” Presence of anxiety symptoms is a potential con-
founder because anxiety symptoms are frequently present in
individuals with depression and are associated with cerebro-
vascular disease independently of depression (27, 28). Gait
speed, a measure of physical performance (29), was the time
needed to walk 6 meters at a usual pace. Hypertension was
defined as systolic pressure .140 mmHg, diastolic pressure
.90 mmHg, and/or use of antihypertensive medication. Body
mass index (BMI) was calculated as measured weight divided
by height squared. Diabetes was defined as a self-reported
doctor’s diagnosis of diabetes, use of blood glucose-lowering
medication, and/or a fasting blood glucose level$7.0 mmol/l.
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Coronary calcium score (categorized into sex-specific quar-
tiles), a measure of atherosclerosis, was based on CT scanning.
TheDigit Symbol SubstitutionTest, ameasure of psychomotor
speech, and the Mini-Mental State Examination (MMSE),
a measure of global cognitive function, were also administered
(18, 30).
Analytic Sample
Of the 3,316 participants who attended the follow-up exami-
nation, 709hadmissingMRIdata, andanother 195hadmissing
data on depressive symptoms at baseline or follow-up. Miss-
ing MRI data was due to contraindications (N=278), refusal/
nonattendance (N=360), or technical reasons (no qualitatively
acceptable data available for all necessary sequences; N=71).
Intheremaining2,412participants, 138wereexcludedbecause
of a diagnosis of dementia at baseline (N=31) or follow-up
(N=107). Finally, participants with presence of depressive
symptoms at baseline (N=325) were excluded. Thus, the final
study sample consisted of 1,949 participants. Participants ex-
cluded for the present analysis, comparedwith thosewhomet
inclusion criteria, weremore likely to be older (mean age: 75.6
years compared with 74.6 years), female (60.8% compared
with 56.6%), and less educated (primary school or less: 23.3%
compared with 18.9%) and to have diabetes (12.4% compared
with 9.1%), hypertension (82.0% compared with 76.9%), and/
or stroke (9.1% compared with 5.2%) (all p values ,0.05).
Statistical Analysis
The percentage of missing values with regard to potential
confounders was minimal (maximum, 1.7%). We imputed
these data usingmultiple imputation by chained equations (10
data sets) (31). White matter hyperintensity volume was log-
arithmically transformed tonormalize its skeweddistribution.
The statistical analysis proceeded in several stages. Logis-
tic regression analysis was used to estimate the association
between markers of baseline CSVD (baseline white matter
hyperintensity volume expressed per 1 higher standard de-
viation [per +1 SD], presence of any (coded 0, 1) subcortical
infarcts, cerebralmicrobleeds andVirchow-Robin spaces, and
total brainparenchymavolumeexpressedper 1 lowerstandard
deviation [per –1 SD]) and incident depressive symptoms.
Analyses were repeated looking prospectively at change in, or
progression of, markers of CSVD as the determinant and
development of depressive symptoms over the same period.
These markers were as follows: an increase in white matter
hyperintensity volume from baseline values (per +1 SD), any
incident (coded0, 1) subcortical infarcts, cerebralmicrobleeds
and Virchow-Robin spaces, and a decrease in total brain pa-
renchyma volume from baseline values (per –1 SD).
We repeated the above analyses for a priori selected brain
regions, which included deep (subcortical) areas (the internal
and external capsules, thalamus, striatum, hippocampus, and
amygdala combined) and frontal, temporal, and occipitopari-
etal lobes. To efficiently summarize the pathology in each of
these regions,wecreatedadichotomouscomposite score.This
was calculated by assigning 1 point per CSVDmarker based on
the following cut-offs: regional white matter hyperintensity
volume, quartile 4 versus quartiles 1–3; subcortical infarcts,
cerebral microbleeds and Virchow-Robin spaces, $1 versus
0 lesion(s) per region; and regional brain parenchymavolume,
quartile 1 versus quartiles 2–4. The points for each marker
were combined to compute a dichotomous composite score
per region, which indicated high ($2 points) or low (0 or 1
point[s]) burden of CSVD. A separate composite score was
computed for baseline CSVD and progression of CSVD over
time, respectively.
Additionally, linear regression was used to evaluate the
association between markers of CSVD and change in the
Geriatric Depression Scale score over time as the outcome.
All models were adjusted for the following potential con-
founders:baselineage,sex,DigitSymbolSubstitutionTestscore,
MMSE score, education level, presence of anxiety symptoms,
gait speed, alcohol use, smoking history, diabetes, BMI, hy-
pertension, coronary calcium score, head coil, and follow-up
time (model 1). Additionally, we carried out further adjustment
for the baseline score on the Geriatric Depression Scale (model
2). The composite scores for each region were additionally
mutually adjusted for each other, with the exception of the
scores for the frontal and deep brain regions, which were not
adjusted for each other because both regions are thought to be
involved inmood regulation (7, 8).We did not adjust the results
for total disease loadbecause total disease load includes the load
per investigated region (as indicated by the composite scores)
and, thus, can be considered an overadjustment (32).
To test the robustness of the results, several sensitivity
analyses were performed. Logistic regression analyses were
repeated with incident depressive symptoms defined only as
a score$6 on the Geriatric Depression Scale as the outcome,
irrespective of new use of antidepressant medication. To
minimize the potential confounding effect of stroke, analyses
were repeated after excluding individuals with baseline
stroke or incident stroke during follow-up. Additionally, to
assess the possibility that depressive symptoms lead to CSVD
(reverse “causality”), analyses were repeated with baseline
presence of depressive symptoms as the exposure variable
(individuals with baseline depressive symptoms were not
excluded, N=325) and markers of progression of CSVD over
timeas theoutcome.All analyseswereconductedwithPASW
Statistics, version 21 (IBM, Armonk, N.Y.).
RESULTS
Themeanageofthestudypopulationatbaselinewas74.6years
[SD=4.6], and 56.6% were women (Table 1). In total, 10.1%
(N=197) of the participants had incident depressive symptoms;
ofwhom, 38.1% (N=75) had a Geriatric Depression Scale score
$6, and 70.6% (N=139) had started using antidepressant
medication (tricyclics, N=22; SSRIs, N=85; and other antide-
pressant medication, N=43). The mean time between the
baseline and follow-up examination was 5.2 years (SD=0.2).
The results of the analyses with regard to markers of base-
line CSVD showed that subcortical infarcts and lower total
572 ajp.psychiatryonline.org Am J Psychiatry 172:6, June 2015
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N % N % N %
Women 1,103 56.6 971 55.4 132 67.0
Education level
Primary 367 18.9 324 18.5 43 21.9
Secondary 996 51.3 897 51.3 99 50.5
College/university 580 29.9 526 30.1 54 27.6
Presence of anxiety symptoms 521 26.7 435 24.8 86 43.7
Smoking status
Ever 1,090 55.9 967 55.2 123 62.4
Never 859 44.1 785 44.8 74 37.6
Diabetes 177 9.1 160 9.1 17 8.6
Hypertension 1,499 76.9 1,347 76.9 152 77.2
Stroke 98 5.0 85 4.9 13 6.6
Mean SD Mean SD Mean SD
Age (years) 74.6 4.6 74.5 4.6 75.2 4.9
Body mass index (kg/m2) 27.2 4.0 27.1 4.0 27.5 4.3
Digit Symbol Substitution Test score
Baseline 33 10 33 10 31 11
Change over time –3 5 –3 5 –4 6
Gait speed (m/second)
Median Interquartile Range Median Interquartile Range Median Interquartile Range
Baseline 0.98 0.92–1.13 0.98 0.91–1.13 0.92 0.84–1.08
Mean SD Mean SD Mean SD
Change over time –0.09 0.23 –0.08 0.22 –0.13 0.25
Mini-Mental State Examination score
Median Interquartile Range Median Interquartile Range Median Interquartile Range
Baseline 28 27–29 28 27–29 28 26–29
Change over time –1 –3 to 1 –1 –3 to 1 –2 –4 to 1
Alcohol use (g/week) 3 0–16 3 0–16 3 0–16
Coronary calcium score (Agatston score) 212 28–744 211 30–751 193 26–693
Brain MRI markers
Total white matter hyperintensity
volume (mL)
Baseline 11 6–21 11 6–20 12 6–22
Mean SD Mean SD Mean SD
Change over time 6 8 5 8 7 8
Total brain parenchyma volume (mL)
Baseline 1,099 104 1,100 104 1,087 106
Change over time –31 23 –31 24 –35 20
Subcortical infarcts
N % N % N %
Baseline presence of any infarct(s) 139 7.1 117 6.7 22 11.2
Any new infarct(s) over time 77 4.0 63 3.6 14 7.1
Cerebral microbleeds
Baseline presence of any microbleed(s) 337 17.3 301 17.2 36 18.3
Any new microbleed(s) over time 348 17.9 308 17.6 40 20.3
Virchow-Robin spaces
Baseline presence of any space(s) 309 15.9 277 15.8 32 16.2
Any new space(s) over time 51 2.6 39 2.2 12 6.1
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brain parenchyma volume had a statistically significant asso-
ciation with higher incidence of depressive symptoms, after
adjustment for potential confounders (model 1 [see Table 2]).
Further adjustment for baseline Geriatric Depression Scale
scores did not materially change these results (model 2).
Additionally, results of the analyses with regard tomarkers
of progression of CSVD over time showed that an increase in
white matter hyperintensity volume over time, incident sub-
cortical infarcts, and Virchow-Robin spaces and a decrease in
total brain parenchyma volume over time had a statistically
significant association with higher incidence of depressive
symptoms (models 1 and 2 [see Table 2]).
Thecompositescoresatbaseline(Figure1A)andthechange
in pathology over time (Figure 1B) in the deep brain region
were most strongly associated with higher incidence of de-
pressive symptoms and reached statistical significance. Fur-
thermore, the composite baseline score of the frontal brain
regionshowedastatistically significantassociationwithhigher
incidence of depressive symptoms.
The results of the analyses with change in Geriatric De-
pression Scale score over time as the outcome were qualita-
tively similar to the results of the analyses with incident
depressive symptoms (models 1 and 2 [see Table 3]). The as-
sociation for a greater Geriatric Depression Scale score over
time was statistically significant for higher baseline white
matter hyperintensity volume, an increase in white matter
hyperintensity volume over time, baseline and incident sub-
cortical infarcts, incident cerebral microbleeds, and baseline
and incidentVirchow-Robinspacesandadecrease in totalbrain
parenchyma volume over time (models 1 and 2 [see Table 3]).
Sensitivity Analyses
Results were qualitatively similar when we repeated the
analyses with incident depressive symptoms defined only
as a Geriatric Depression Scale score$6, irrespective of new
use of antidepressant medication (see Table S1 in the data
supplement accompanying the online version of this article).
When we excluded individuals with baseline stroke or in-
cident stroke during follow-up (N=152), results did not ma-
terially change (see Table S2 in the online data supplement).
Presence of depressive symptoms at baseline was not sig-
nificantly associated with markers of progression of CSVD
(see Table S3 in the data supplement).
DISCUSSION
The present study investigated the association between
markers of CSVD and incident depressive symptoms and had
two main findings. First, various markers of CSVD were as-
sociated with higher incidence of depressive symptoms. This
associationwas statistically significant for an increase inwhite
matter hyperintensity volume over time, baseline and incident
subcortical infarcts, incident Virchow-Robin spaces, lower
total brain parenchyma volume at baseline, and a decrease in
total brain parenchyma volume over time. These results were
independent of cognitive function, education level, physical
TABLE 2. Associations Between Baseline Values and Progression






Ratio 95% CI p
White matter hyperintensity
volume (% intracranial volume)
Per +1 standard deviation volume
at baseline
Model 1 1.04 0.89–1.21 0.67
Model 2 1.02 0.88–1.19 0.78
Per +1 standard deviation
volume change over time
Model 1 1.24 1.09–1.42 0.002
Model 2 1.21 1.06–1.39 0.007
Subcortical infarcts
Baseline presence of any
infarct(s) versus no infarcts
Model 1 1.90 1.15–3.14 0.01
Model 2 1.83 1.10–3.05 0.02
Any new infarct(s) over time
versus no new infarcts
Model 1 2.39 1.28–4.48 0.007
Model 2 2.31 1.21–4.39 0.01
Cerebral microbleeds
Baseline presence of any
microbleed(s) versus no
microbleeds
Model 1 1.15 0.77–1.72 0.50
Model 2 1.10 0.73–1.66 0.64
Any new microbleed(s) over
time versus no new
microbleeds
Model 1 1.31 0.92–1.87 0.16
Model 2 1.36 0.98–1.86 0.12
Virchow-Robin spaces
Baseline presence of any
space(s) versus no spaces
Model 1 1.09 0.73–1.61 0.69
Model 2 1.08 0.70–1.66 0.71
Any new space(s) over time
versus no new spaces
Model 1 3.44 1.71–6.91 0.001
Model 2 3.75 1.83–7.68 ,0.001
Total brain parenchyma
volume (% intracranial volume)
Per –1 standard deviation
volume at baseline
Model 1 1.23 1.05–1.45 0.01
Model 2 1.23 1.04–1.45 0.02
Per –1 standard deviation volume
change over time
Model 1 1.30 1.08–1.57 0.006
Model 2 1.32 1.09–1.59 0.004
a Model 1 adjusted for baseline age, sex, Digit Symbol Substitution Test score,
Mini-Mental State Examination score, education level, presence of anxiety
symptoms, gait speed, alcohol use, smoking status, diabetes, body mass
index, hypertension, coronary calcium score, head coil, and follow-up time.
Model 2 additionally adjusted for baseline score on the 15-item Geriatric
Depression Scale.
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performance, anxiety symptoms, and cardiovascular factors.
Additionally, resultswere qualitatively similarwhen change in
the score on theGeriatricDepressionScale over timewas used
as the outcome instead of incident depressive symptoms.
Second,CSVDlocated in thedeepbrain region, comparedwith
other brain regions, wasmore strongly associated with higher
incidence of depressive symptoms. To our knowledge, this is
theclearestdemonstration todate thatCSVDisa risk factor for
depressive symptoms.
Ourfindingsare inaccordancewithpreviouscross-sectional
studies (13, 14, 33), which consistently have shown an associ-
ation between markers of CSVD and depression. Additionally,
two previous, smaller longitudinal studies, the 3-City-Dijon
Study (13) and the LADIS (Leukoaraiosis and Disability)
Study (12), found an association between higher white mat-
ter hyperintensity volume at baseline and higher incidence
of depressive symptoms after a follow-up of 4 and 3 years,
respectively. Furthermore, theSMART(SecondManifestations
of ARTerial disease-Magnetic Resonance)-Medea Study (9)
found an association between lacunar infarcts in deep white
matter tracts and an increased severity and more fluctuating
course of depressive symptoms, in particular motivational/
apathy related-symptoms of depression, during a follow-up
of 3.5 years. The Cardiovascular Health Study (16) and a neu-
roimaging substudy of the Rotterdam Study (15) showed an
association between higher white matter hyperintensity vol-
ume and/or cerebral infarcts, on the one hand, and worsening
and recurrence of depressive symptoms, on the other, after 4
years of follow-up. In contrast, two other longitudinal studies,
a post hoc analysis of a clinical trial (17) and the Baltimore
Longitudinal Study of Aging (11), did not find any association
between white matter hyperintensity volume at baseline and
incidentdepressivesymptoms.However, the latterstudieswere
relatively small (N,550) (11, 17) and/or had a relatively short
follow-up duration (,3 years) (17), which may have led to
an underestimation of the association between CSVD and de-
pressive symptoms. The present study extends previous
research because of its large population-based sample of older
FIGURE1. AssociationsBetweenBrainRegion-SpecificCompositeScores forBaselineValues (PanelA)andProgressionOverTime (PanelB)
of Cerebral Small Vessel Disease (CSVD) and Incident Depressive Symptomsa
2.25 (1.53 to 3.31)
1.86 (1.46 to 2.37)
0.78 (0.44 to 1.40)
0.76 (0.45 to 1.28)
2.11 (1.30 to 3.42)
1.39 (0.85 to 2.28)
0.78 (0.44 to 1.39)
1.62 (0.95 to 2.75)
Odds ratio (95% CI)A











a Composite scores indicate high versus low burden of CSVD per region. The composite scores were mutually adjusted for each other (except for the
frontal and deep brain regions, which were not adjusted for each other) and for all potential confounders.
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individuals, long follow-up duration, the comprehensive brain
MRI assessment of a wide spectrum of CSVD markers deter-
mined at baseline and at follow-up, and the extensive charac-
terization of participants that enabled us to adjust for a series
of potential confounders.
CSVD may lead to depres-
sive symptoms through damage
to deep and frontal brain struc-
tures involved in mood regu-
lation (7, 8). In accordance, the
present study found that CSVD
in the deep brain region, com-
pared with other regions, was
more strongly associated with
higher incidence of depressive
symptoms, although the 95%
confidence intervals of the
odds ratios for disease in the
deep brain region did overlap
with those of other regions.
However, other underlying
mechanisms may explain the
observed associations. First, it




symptoms represent an early
manifestation of (vascular) de-
mentia (34). For the present
study, however, we excluded
individuals with dementia at
baseline or at follow-up. In
addition, our results were ad-
justed for scores on the Digit
Symbol Substitution Test and
the MMSE, tests that eval-
uate multiple cognitive func-
tions(35).Second,other factors
may be independently related
to both CSVD and depressive
symptoms, such as anxiety, car-
diovascular factors, and stroke.
However, the associations
between CSVD and incident
depressive symptoms were




we excluded individuals with
stroke. Third, we cannot ex-
clude the possibility that the
observed associations reflect
reverse causation. Indeed, pre-
vious studies (36, 37) have
shown an association between depression and incident car-
diovascular disease, including cerebrovascular disease. Al-
though it is not fully understoodhowdepressionmight lead to
vascular disease, possible mechanisms include low-grade in-
flammation, endothelial dysfunction, platelet dysfunction, and
TABLE 3. Associations Between Baseline Values and Progression Over Time of Cerebral Small Vessel
Disease Markers and Change in Score on the 15-Item Geriatric Depression Scale Over Timea
Determinant and Model
Change in Geriatric Depression Scale Score Over Time
b Coefficient 95% CI p
White matter hyperintensity volume
(% intracranial volume)
Per +1 standard deviation volume at
baseline
Model 1 0.11 0.04 to 0.18 0.003
Model 2 0.11 0.04 to 0.18 0.001
Per +1 standard deviation volume change
over time
Model 1 0.16 0.09 to 0.24 ,0.001
Model 2 0.20 0.13 to 0.26 ,0.001
Subcortical infarcts
Baseline presence of any infarct(s) versus
no infarcts
Model 1 0.27 –0.01 to 0.54 0.05
Model 2 0.34 0.08 to 0.59 0.01
Any new infarct(s) over time versus no
new infarcts
Model 1 0.34 –0.02 to 0.70 0.07
Model 2 0.40 0.06 to 0.74 0.02
Cerebral microbleeds
Baseline presence of any microbleed(s)
versus no microbleeds
Model 1 –0.03 –0.22 to 0.15 0.73
Model 2 –0.02 –0.18 to 0.17 0.98
Any new microbleed(s) over time versus
no new microbleeds
Model 1 0.20 0.02 to 0.38 0.03
Model 2 0.18 0.01 to 0.36 0.04
Virchow-Robin spaces
Baseline presence of any space(s) versus
no spaces
Model 1 0.19 –0.00 to 0.38 0.05
Model 2 0.18 0.00 to 0.36 ,0.05
Any new space(s) over time versus no
new spaces
Model 1 0.80 0.37 to 1.22 ,0.001
Model 2 0.74 0.34 to 1.13 0.001
Total brain parenchyma volume
(% intracranial volume)
Per –1 standard deviation volume at
baseline
Model 1 0.04 –0.04 to 0.12 0.32
Model 2 0.06 –0.01 to 0.14 0.11
Per –1 standard deviation volume
change over time
Model 1 0.08 0.02 to 0.15 0.02
Model 2 0.08 0.01 to 0.15 0.02
a Model 1 adjusted for baseline age, sex, Digit Symbol Substitution Test score, Mini-Mental State Examination score,
education level, presence of anxiety symptoms, gait speed, alcohol use, smoking status, diabetes, body mass index,
hypertension, coronary calciumscore, headcoil, and follow-up time.Model 2additionally adjusted forbaseline scoreon
the 15-item Geriatric Depression Scale.
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unfavorable lifestyle habits (38). It is unclear, however, why
depression would lead to vascular disease in specific brain
regions (e.g., the deep brain region involved in mood regu-
lation). Additionally, in the present study, presence of depres-
sive symptoms at baseline was not found to have a statistically
significant association with markers of progression of CSVD
over time, although the 95% confidence intervals of the effect
estimates do not exclude the possibility of such an association.
Fourth, it has been suggested that associations between CSVD
and depression may be (partially) attributable to apathy (39).
Apathy overlaps with depression but may be a distinct syn-
drome (40). In the present study, we did not evaluate apathy,
and this issue requires further study.
Our study showed that most markers of progression of
CSVD over time were associated with incident depressive
symptoms but only somemarkers of baseline CSVD. This may
be due to the design of our study with exclusion of individuals
with depressive symptoms at baseline. Thismay have led to an
underestimationoftheassociationbetweenbaselineCSVDand
development of depressive symptoms but not between pro-
gression of CSVDover time and depressive symptoms because
individuals with depressive symptoms at baseline were most
likely those with the strongest association between lifetime
accumulation of CSVD (which is reflected by baseline CSVD)
and depressive symptoms.
We analyzed depressive symptoms as both a dichotomous
and a continuous outcome. The results of these analyses were
qualitatively similar, except that more associations were sta-
tistically significantwithchange in thecontinuous scoreonthe
Geriatric Depression Scale than with the dichotomous in-
cident depressive symptoms variable. This difference may be
due to the fact that, in general, analyses with a continuous
outcome have higher statistical power than analyses with a
dichotomous outcome. Indeed, studying depression on a con-
tinuum has the merit that not only information on extremes is
used but that all available information is exploited.
Thereareanumberof limitations to thepresent study.First,
incident depressive symptomswere assessed by questionnaire
and use of antidepressant medication but not by a structured
interview. Therefore, no information was available on clinical
depression. Nevertheless, the sensitivity and specificity of ques-
tionnaire measures compared with a depression diagnosis
based on a structured interview are high (.80%) (20). Yet, the
prevalence of depressive symptoms is greater, in particular
in older individuals (2, 4). Furthermore, late-life depressive
symptoms, even in the absence of a diagnosis of major de-
pressive disorder, are associated with greatly increased mor-
bidity and mortality risk (5, 6). Second, misclassification of
incident depressive symptoms may have occurred because
antidepressant medication is also prescribed for other reasons.
However, the results were qualitatively similarwhen Geriatric
Depression Scale scores alonewere used as the outcome.Third,
thepresent study is thefirst, to our knowledge, to evaluate the
associationbetweenbrain region-specific composite scores
and depressive symptoms, and further study is therefore
needed toconfirmthepresentfindings (e.g., using voxel-based
morphometric analysis). Fourth, a limitation of the analysis
with markers of progression of CSVD over time as the deter-
minant is that progression of CSVD and incident depressive
symptoms occur in the same time interval and cannot be
assigned to a given time point within this interval. Finally, we
used cerebral atrophy and Virchow-Robin spaces as markers
ofCSVD.Cerebral atrophy is, however, an indirectmeasure
of vascular disease and is also strongly determined by other
factors, in particular the process of neurodegeneration. We
therefore cannot exclude the possibility that the association
between lower total brainparenchymavolumeanddepressive
symptoms is a result of factors other than CSVD. Furthermore,
theetiologyofVirchow-Robin spaces iscurrently incompletely
understood, and this issue requires further study.
In conclusion, the present study shows that most markers
of progression of CSVD over time and only some markers of
baselineCSVDare independentlyassociatedwithaconcurrent
development of higher incident depressive symptoms. From
a clinical point of view, this association is important because it
suggests that CSVD is a target for treatment and prevention
strategies of late-life depression. Further study is needed to
elucidatewhich factors contribute toCSVD andwhether such
factors can be therapeutic targets for late-life depression.
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